Vanda Shares Rise 7.9% on NEREUS Launch

Vanda Pharmaceuticals announced commercial availability of NEREUS™ (tradipitant) for adult motion‑sickness prevention across the United States.
The drug, first new prescription for motion sickness in over 40 years, is sold at $85 cash‑pay versus $255 list price.
FDA approved NEREUS™ on Dec 30 2025 after Phase 3 trials (Motion Syros, Motion Serifos) showed significant vomiting prevention versus placebo.
Vanda’s shares rose about 7.9% following the launch, while Atossa Genetics saw a 10.3% jump due to ticker confusion.